Fig. 2

Computed tomography scans from a patient with metastatic Merkel cell carcinoma treated with avelumab. a PD at baseline (March 2017), b partial response at 18 months after starting avelumab treatment (September 2018), and c PD in September 2020 after stopping avelumab treatment in February 2020; the patient has since restarted avelumab treatment. Images were provided by Dr. Chiarion Sileni. PD progressive disease